| dbo:abstract
|
- Merimepodib ist ein experimenteller Arzneistoff, dessen Wirksamkeit als zusätzliches Mittel in den 2000er-Jahren zur damals bestehenden Peginterferon α/Ribavirin-Therapie in der Therapie der Hepatitis C in klinischen Studien behauptet wurde. Merimepodib hemmt selektiv die zelluläre Inosinmonophosphat-Dehydrogenase (IMPDH). Es hat keinen spezifischen antiviralen Effekt und kein virales Protein als Target, jedoch eine gewisse Wirkung in Kombination mit Ribavirin auf HCV-Replikon-enthaltende Zellkulturen. Es zeigte bei therapierefraktären Patienten in einer größeren Studie mit 286 Patienten keinen Effekt oder zusätzlichen Nutzen. Seit Einführung der hochwirksamen, direkt antiviral wirkenden (DAA, direct antiviral agent) Arzneistoffe zur Therapie der Hepatitis C, ist seine Anwendung obsolet. (de)
- Merimepodib (VX-497) is a drug which acts as an inhibitor of the enzyme inosine monophosphate dehydrogenase, which is required for the synthesis of nucleotide bases containing guanine. This consequently inhibits synthesis of DNA and RNA, and results in antiviral and immunosuppressive effects. It progressed as far as Phase 2b human clinical trials against Hepatitis C but showed only modest benefits in comparison to existing treatments, however it continues to be researched, and also shows activity against other viral diseases such as Zika virus and foot and mouth disease virus. Merimepodib was investigated in combination with remdesivir in a phase 2 clinical trial in the U.S. as a potential treatment of COVID-19 by ViralClear Pharmaceuticals. The trial stopped in October 2020, and the company announced in a news release that it was "unlikely that the trial would meet its primary safety endpoints", and that it "does not intend to further develop merimepodib". (en)
|
| dbo:casNumber
| |
| dbo:chEMBL
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 5223 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chembl
| |
| dbp:chemspiderid
| |
| dbp:drugbank
| |
| dbp:h
| |
| dbp:iupacName
|
- [-oxolan-3-yl] N-[methyl]carbamate (en)
|
| dbp:kegg
| |
| dbp:legalUs
|
- Investigational drug (en)
|
| dbp:molecularWeight
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pubchem
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- JBPUGFODGPKTDW-SFHVURJKSA-N (en)
|
| dbp:unii
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| rdf:type
| |
| rdfs:comment
|
- Merimepodib ist ein experimenteller Arzneistoff, dessen Wirksamkeit als zusätzliches Mittel in den 2000er-Jahren zur damals bestehenden Peginterferon α/Ribavirin-Therapie in der Therapie der Hepatitis C in klinischen Studien behauptet wurde. (de)
- Merimepodib (VX-497) is a drug which acts as an inhibitor of the enzyme inosine monophosphate dehydrogenase, which is required for the synthesis of nucleotide bases containing guanine. This consequently inhibits synthesis of DNA and RNA, and results in antiviral and immunosuppressive effects. It progressed as far as Phase 2b human clinical trials against Hepatitis C but showed only modest benefits in comparison to existing treatments, however it continues to be researched, and also shows activity against other viral diseases such as Zika virus and foot and mouth disease virus. (en)
|
| rdfs:label
|
- Merimepodib (de)
- Merimepodib (en)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
